Skip to main content
MyPeptideMatch

Evernow Review

Women's menopause HRT telehealth

TelehealthCompounded medicationsHormone Optimization
7.5/10our editorial score
$35/mo
starting price
Visit Evernow

Our verdict

Women's menopause and perimenopause telehealth offering estrogen, progesterone, and related HRT with video and messaging care nationwide from $35/mo.

Pros & cons

Pros

  • Menopause-specialist clinicians
  • Affordable $35/mo entry
  • Video + messaging care nationwide

Cons

  • Menopause/HRT focus only
  • No peptide offerings

Pricing & how it works

Starting price
$35/month
Consultation
Live video visit with a licensed clinician
Medication type
Compounded (503A/503B pharmacies)
Availability
United States

Evernow FAQ

Is Evernow legit?

Evernow is a US-based telehealth provider that connects patients with licensed clinicians and ships prescriptions from partner pharmacies. As with any telehealth service, treatment eligibility is determined during a medical consultation.

How much does Evernow cost?

Evernow starts at about $35/month. Your final cost depends on the medication and plan selected during your consultation; lab work and shipping may be billed separately.

What does Evernow offer?

Evernow focuses on hormone optimization.

How do Evernow consultations work?

Evernow uses live video visit with a licensed clinician. After intake, a licensed clinician reviews your information and, if appropriate, issues a prescription that ships to your door.

Does Evernow prescribe brand-name or compounded medication?

Evernow primarily works with compounded medications dispensed by licensed 503A/503B pharmacies rather than FDA-approved brand-name products.

Ready to start with Evernow?

Affiliate disclosure: Some links on this page are affiliate links — if you start treatment through one, we may earn a commission at no additional cost to you. Editorial rankings and opinions are independent of commercial relationships. This page is for informational purposes only and is not medical advice. See our affiliate disclosure.